Superworth

Black Diamond Therapeutics revenue BDTX

Sales by quarter and over the last twelve months, from 2024.

Last 12 months, to Jun 30, 2026
$0
Latest quarter, Q2 FY26
$0
Fiscal year 2025
$70M

Black Diamond Therapeutics' revenue was $0 over the twelve months to Jun 30, 2026, down 100% on a year earlier.

In its latest quarter, Q2 FY26, it was $0.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$70Mn/a
FY2024$0n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$0n/a$0
Q1 FY26$0−100%$0
Q4 FY25$0n/a$70M
Q3 FY25$0n/a$70M
Q2 FY25$0n/a$70M
Q1 FY25$70Mn/a$70M
Q4 FY24$0n/a$0
Q3 FY24$0n/an/a
Q2 FY24$0n/an/a
Q1 FY24$0n/an/a

Against its peers

Companies in Healthcare nearest Black Diamond Therapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
BDTXBlack Diamond Therapeutics$0−100% a year
KEQUKewaunee Scientific$277.2M+5% a year
ICCCImmucell$30.7M+8% a year
LFVNLifevantage$182.6M−20% a year
SPROSpero Therapeutics$47M−3% a year
PDEXPro DEX$77.5M+16% a year
PLXProtalix BioTherapeutics$80.6M+30% a year
APTAlpha Pro Tech$61.9M+6% a year
NATRNatures Sunshine Products$492M+7% a year
ELMDElectromed$73.8M+15% a year
UTMDUtah Medical Products$36.1M−7% a year
Peer median$75.7M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Black Diamond Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.